Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells

Oncogene

Volumn 30, Issue 43, 2011, Pages 4447-4452

  Uzawa, K ^a,b   Ishigami, T ^a   Fushimi, K ^a   Kawata, T ^a   Shinozuka, K ^c   Kasamatsu, A ^a   Sakamoto, Y ^a   Ogawara, K ^a   Shiiba, M ^a   Bukawa, H ^a   Ito, H ^a   Tanzawa, H ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

FGFR3; fibroblast growth factor receptor 3 gene; radiosensitivity; squamous cell carcinoma

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RADIOSENSITIVITY; RNA INTERFERENCE; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; PYRIMIDINES; RADIATION TOLERANCE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 80055033312     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.159     Document Type: Article

References (18)

1. Bar-Sagi D, Feramisco JR. (1985). Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 42: 841-848.
2. Chesi M, Nardini E, Brents LA, Schro?ck E, Ried T, Kuehl WM et al. (1997). Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264. (Pubitemid 27280209)
3. Eswarakumar VP, Lax I, Schlessinger J. (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149. (Pubitemid 40616112)
4. Fowler JF, Denekamp J, Delapeyre C, Harris SR, Sheldon PW. (1974). Skin reactions in mice after multifraction x-irradiation. Int J Radiat Biol 25: 213-223.
5. Friesel RE, Maciag T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 9: 919-925.
6. Henson BJ, Gollin SM. (2010). Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res 128: 192-198.
7. Ishigami T, Uzawa K, Higo M, Nomura H, Saito K, Kato Y et al. (2007). Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells. Int J Cancer 120: 2262-2270. (Pubitemid 46555867)
8. Johnson DE, Williams LT. (1993). Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60: 1-41.
9. Knowles MA. (2008). Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 4: 71-83. (Pubitemid 351372608)
10. Koziczak M, Holbro T, Hynes NE. (2004). Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23: 3501-3508. (Pubitemid 38658416)
11. Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V et al. (2006). MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 15: 3465-3471.
12. Noda M, Ko M, Ogura A, Liu DG, Amano T, Takano T et al. (1985). Sarcoma viruses carrying ras oncogenes induce differentiationassociated properties in a neuronal cell line. Nature 318: 73-75. (Pubitemid 16230339)
13. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B et al. (2009). The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 15: 8645-8651.
14. Rosty C, Aubriot MH, Cappellen D, Bourdin J, Cartier I, Thiery JP et al. (2005). Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer 4: 15.
15. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K. (2003). Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107: 1030-1037. (Pubitemid 37429847)
16. Studer G, Zwahlen RA, Graetz KW, Davis BJ, Glanzmann C. (2007). IMRT in oral cavity cancer. Radiat Oncol 2: 16.
17. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, Dittmann K. (2006). Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12: 4119-4126. (Pubitemid 44078101)
18. Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M et al. (2004). Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103: 3521-3528. (Pubitemid 38525687)